key: cord-1005249-yqvw3que
authors: Pappa, S.; Barmparessou, Z.; Sakka, E.; Patrinos, S.; Sakkas, N.; Athanasiou, N.; Kalomenidis, I.; Katsaounou, P.
title: P.0797 Effects on mental health, sleep and quality of life in hospitalized patients with COVID-19 infection
date: 2021-12-30
journal: Eur Neuropsychopharmacol
DOI: 10.1016/j.euroneuro.2021.10.859
sha: 4d1357a08eb7b15d0d13b7153f68ecea8203b7e4
doc_id: 1005249
cord_uid: yqvw3que

nan

After 6 months of follow-up, we found a sustained clinical improvement in all GCI subdomains. The limitations of this study are the instrument limitations, a small and convenient sample, lack of a control group and presence of selection and information biases. Conclusions: Our interview-based study suggests that cariprazine might improve negative symptoms in real-world clinical practice. This has been proposed in a recent paper by a panel of experts in the field of psychotic disorders [4] . Our sample was composed of patients with moderate to severe negative and positive symptoms, treated with more than one pharmacological agent. These patients are usually excluded from clinical trials, albeit polypharmacy being common in clinical practice [5] . We propose that cariprazine could be an effective and acceptable treatment for negative symptoms in difficult to treat populations. Further studies are important to clarify this hypothesis. This finding was consistent across all recorded psychological outcomes i.e. depression (p = 0.004), anxiety (p = 0.017), traumatic stress (p < 0.001), fear (p < 0.001) and insomnia (p = 0.002). In addition, differences in prevalence rates between genders were particularly marked for moderate levels of depression and traumatic stress and for severe levels of anxiety.

Smoking and comorbidities were not found to significantly correlate with the presence of affective symptoms or sleep dysfunction. However, an association was observed between severity and the existence of comorbidity with the proportion of patients with comorbidities increasing from 67.5% of the patients with minimal depression to 91.43% to those with mild and 80% with moderate depression (pvalue = 0.018). Finally, quality of life was worse for patients that have had an admission in the ICU (EQ-5D-5L: 15.82 ± 5.27) compared to those who were hospitalized but did not require ICU treatment (EQ-5D-5L: 8.39 ± 2.81) (pvalue < 0.001). Conclusion: COVID-19 disease can have a significant psychological impact on hospitalized patients and particularly women despite the relative less severe course of their illness. This finding is in line with a previous study, showing that, despite significantly lower levels of baseline inflammatory markers, female patients suffered more for both anxiety and depression at one-month follow-up following hospital admission (3). Regardless of potential sex differences, the prevalence of moderate and severe mental illness symptoms in COVID-19 patients may be higher compared with the general population or other high risk groups such as different patient groups or healthcare workers [2] [3] [4] . Our results highlight the need for appropriate interventions to promote physical and mental wellbeing of COVID-19 survivors and cater for long-term needs.

Background : Patients with Bipolar Disorder (BD) are highly vulnerable to stressful events and can experience a wide range of symptoms and emotions in the immediate aftermath of exposure, leading to a later onset of Post-traumatic stress disorder (PTSD) [1] . Peritraumatic Distress (PD) encompasses several negative physiological, emotional, and cognitive responses that occur immediately after the event, such as: a sense of personal life threat; feelings of fear helplessness and horror; guilt, shame and anger; loss of bowel and bladder control; shaking, trembling, and increased heart rate [ 2 , 3 ] . Increasing studies highlighted that PD may predict the development of PTSD symptoms in subjects exposed to potential traumatic events [4] . However, scant data are still available about the effects of the COVID-19 pandemic on the clinical course of BD [5] . Objective: The aim of this study was to investigate PD symptoms related to the COVID-19 emergency in a sample of patients with BD in euthymic phase at the time of the acute phase of the pandemic and their possible correlation with PTSD symptoms emerged within a 6-month follow-up. Methods : Ninety-two patients with BD were enrolled at the Psychiatric Clinic of the University of Pisa (Italy) during the first wave of the COVID-19 pandemic in Italy and assessed at baseline (T0) by means of the Impact Event Scale -revised (IES-R), to explore PTSD symptoms, and the Peritraumatic Distress Inventory (PDI), to investigate PD; the IER-R was submitted again after a 6-month (T1) follow-up. Com-

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and metaanalysis with comparison to the COVID-19 pandemic

The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis

Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors

Traumatic Stress and Burnout in Healthcare Workers during the COVID-19 Pandemic in Greece: A Multi-Center, Cross-Sectional Study